SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-091210
Filing Date
2024-08-06
Accepted
2024-08-06 07:42:02
Documents
70
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q kpti-20240630.htm   iXBRL 10-Q 2721071
2 EX-31.1 kpti-ex31_1.htm EX-31.1 11590
3 EX-31.2 kpti-ex31_2.htm EX-31.2 11626
4 EX-32.1 kpti-ex32_1.htm EX-32.1 7175
5 EX-32.2 kpti-ex32_2.htm EX-32.2 7189
  Complete submission text file 0000950170-24-091210.txt   9730552

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kpti-20240630.xsd EX-101.SCH 1332734
72 EXTRACTED XBRL INSTANCE DOCUMENT kpti-20240630_htm.xml XML 1585167
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

IRS No.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36167 | Film No.: 241177138
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)